NFKB1 and acute lymphoblastic leukemia: However, therapy using NF-κB/IKKβ inhibitors can only be envisaged when firm pre-clinical or clinical evidence that the canonical NF-κB activation is important for the maintenance of human T-ALL in vivo is obtained.